Apr 17, 2019
Forbes Names BioMarin 4th Best Midsize Employer in America
Feb 21, 2019
BioMarin Announces Full Year and Fourth Quarter 2018 Results
Feb 07, 2019
Sanofi delivers 2018 business EPS growth of 5.1% at CER
Nov 16, 2018
Johnson Fistel Files Class Action Suit Against Trevena, Inc.
Nov 12, 2018
BioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical'
Nov 07, 2018
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York
Oct 25, 2018
BioMarin Announces Third Quarter 2018 Results
Sep 05, 2018
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
Aug 17, 2018
2018 Mucopolysaccharidosis Disorders Drug Development Pipeline Review
Aug 10, 2018
First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
Aug 02, 2018
BioMarin Announces Second Quarter 2018 Results
Jul 10, 2018
ArmaGen's AGT-181 52-Week Phase 1/2 Proof-of-Concept Study Results Published in Orphanet Journal of Rare Diseases
Jul 09, 2018
BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive
Jun 12, 2018
REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I
Jun 04, 2018
Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis, H1 2018 with Profiles of ArmaGen, Angiochem and JCR Pharmaceuticals
May 24, 2018
BioMarin Receives Standard Approval for Palynziq(TM) (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease
May 15, 2018
REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation
Apr 25, 2018
BioMarin Announces First Quarter 2018 Financial Results
Feb 22, 2018
BioMarin Announces Fourth Quarter and Full Year 2017 Financial Results
Feb 08, 2018
ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I